Pharmacoeconomic evaluation of Bimekizumab based on value-based pricing
ABSTRACT:OBJECTIVE In this study,pharmacoeconomic evaluation was conducted to compare bimekizumab and secukinumab in the treatment of moderate-to-severe plaque psoriasis,and pricing recommendations for bimekizumab were given based on its value.METHODS From the perspective of medical and health care in China,a Markov model was constructed using TreeAge Pro software to evaluate the total costs and overall health outcomes of bimekizumab under different pricing com-pared to secukinumab monotherapy strategies.Sensitivity analysis was employed to verify the robustness of the model.The parameters and data in this model were derived from published literature and official websites.RESULTS When the price of bimekizumab was 1 377 yuan/160 mg,the total cost of bimekizumab group was 222 073 yuan,the total cost of secukinumab group was 190 425 yuan,with an incremental cost-effectiveness ratio(ICER)of 85 662.90 yuan·QALY-1,nearly matching the per capita GDP in 2022(85 698 yuan).When the price of bimekizumab was 1 848 yuan/160mg,the total cost of bimekizumab group was 285 475 yuan,the total cost of secukinumab group was 190 425 yuan,with an ICER of 257 275.77 yuan·QALY-1,nearly 3 times the per capita GDP in 2022(257 094 yuan).When the price of bimekizumab and secukinumab were the same,ICER was 16 799.14 yuan·QALY-1,which indicated that bimekizumab is more cost-effective.CONCLUSION The value-based pricing suggests that compared with secukinumab,bimekizumab should be priced below 1 377 yuan/160mg when willing-ness to pay(WTP)is 85 698 yuan·QALY-1,and below 1 848 yuan/160 mg when WTP is 257,094 yuan·Q ALY-1 to have a cost-effectiveness advantage.
NETL
NSTL
万方数据
